Practice guideline for the histopathological diagnosis of mesothelioma (2025 version)

Expert Committee on Pathology of Chinese Research Hospital Association; Professional Committee on Tumor Pathology of Shanghai Anticancer Association

doi:10.19401/j.cnki.1007-3639.2024.12.009

您当前的位置：

首页 >

文章列表页 >

Practice guideline for the histopathological diagnosis of mesothelioma (2025 version)

Short Article | 更新时间：2025-12-31

- Practice guideline for the histopathological diagnosis of mesothelioma (2025 version)
- China Oncology Vol. 34, Issue 12, Pages: 1144-1163(2024)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2024.12.009
  CLC：
- Received：10 November 2024，
  
  Published：30 December 2024
- 稿件说明：
移动端阅览
Expert Committee on Pathology of Chinese Research Hospital Association, Professional Committee on Tumor Pathology of Shanghai Anticancer Association. Practice guideline for the histopathological diagnosis of mesothelioma (2025 version)[J]. China Oncology, 2024, 34(12): 1144-1163.
DOI：

Expert Committee on Pathology of Chinese Research Hospital Association, Professional Committee on Tumor Pathology of Shanghai Anticancer Association. Practice guideline for the histopathological diagnosis of mesothelioma (2025 version)[J]. China Oncology, 2024, 34(12): 1144-1163. DOI： 10.19401/j.cnki.1007-3639.2024.12.009.

摘要

为了进一步提高中国间皮瘤的病理学诊断水平和病理学报告规范性，为病理科医师在临床实践中提供借鉴证据，为临床治疗和患者预后判断提供重要信息，中国研究型医院学会病理学专业委员会和上海市抗癌协会肿瘤病理专业委员会组织138位来自国内28个省市自治区的专家，组建《间皮瘤组织病理学诊断临床实践指南（2025年版）》制定专家团，设立指南工作组，涵盖病理、影像、肿瘤内科、胸外科、肿瘤预防、流行病学与卫生统计学等多学科，本着科学化、规范化、透明化和制度化的原则，基于现有循证医学证据，在文献检索和证据收集基础上，围绕间皮瘤病理学诊断最新进展，聚焦间皮瘤病理学诊断原则、免疫组织化学标志物和分子病理学检测，依据推荐分级的评估、制订和评价系统（Grading of Recommendations，Assessment，Development and Evaluation，GRADE）对循证医学证据质量和专家推荐意见强度进行质量等级分级和证据综合，采用德尔菲问卷调查法和共识会议法相结合，就间皮瘤病理学诊断相关“陈述”进行专家函询和投票审议，去重、合并和汇总临床问题，形成推荐意见。参照卫生保健实践指南报告条目（the Reporting Items for practice Guidelines in HealThcare，RIGHT）起草《间皮瘤组织病理学诊断临床实践指南（2025年版）》初稿，召开专家会议进行审核，并送外审专家评议，综合审定意见进行修改，形成终稿。本指南的目标人群为间皮瘤患者，使用人群为从事间皮瘤病理学诊断和辅助检测的医务工作者。本指南在国际实践指南注册与透明化平台（

http://www.guidelines-registry.org

）进行中英文双语注册，注册号为PREPARE-2024CN672，所撰写的指南计划书可从平台获取。

Abstract

To improve the quality of pathologic diagnosis and enhance the standardization in pathological report of mesothelioma

Expert Committee on Pathology of Chinese Research Hospital Association and Professional Committee on Oncopathology of Shanghai Anticancer Association set up an expert team and establish guideline working groups

which embrace139 mutidisciplinary experts nationwide covering pathology

radiology

oncology

thoracic surgery

epidemiology and health statistics. Based on the principles of scientification

standardization

transparency and institutionalization with adherence to the international guidelines writing standards and guiding principles for the formulation/revision of clinical diagnosis and treatment guidelines in China

experts adopt evidence-based medicine methods

keep updated on the newest progress

focus on the diagnostic principles

immunohistochemistry and molecular pathology

establish quality evaluation and evidence summary

utilize the GRADE system and Delphi method in combination with multidisciplinary expert meetings

draft

modify and finalize this version of practice guideline for the histopathological diagnosis of mesothelioma. The target population and audience of the guideline center on patients with mesothelioma

whereas the users are medical staff engaged in pathological diagnosis and auxiliary testing of mesothelioma. This guideline has been registered in Practice Guide Registration for TransPAREncy (PREPARE) (

http://www.guidelines-registry.org

)

with registration number PREPARE-2024CN672. The plan of the guideline can be obtained from the platform.

关键词

Keywords

references

ZHAI Y R , HUI Z G , CHEN W Q , et al . The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016-2030 [J ] . Transl Lung Cancer Res , 2022 , 11 ( 12 ): 2403 - 2411 .

陈耀龙 , 杨克虎 , 王小钦 , 等 . 中国制订/修订临床诊疗指南的指导原则(2022版) [J ] . 中华医学杂志 , 2022 , 102 ( 10 ): 697 - 703 .

CHEN Y L , YANG K H , WANG X Q , et al . Guiding principles for formulating/revising clinical diagnosis and treatment guidelines in China (2022 edition) [J ] . Natl Med J China , 2022 , 102 ( 10 ): 697 - 703 .

CHEN Y L , YANG K H , MARUŠIC A , et al . A reporting tool for practice guidelines in health care: the RIGHT statement [J ] . Ann Intern Med , 2017 , 166 ( 2 ): 128 - 132 . DOI: 10.7326/M16-1565 http://doi.org/10.7326/M16-1565

O’NEIL J D , ROS P R , STORM B L , et al . Cystic mesothelioma of the peritoneum [J ] . Radiology , 1989 , 170 ( 2 ): 333 - 337 .

SUN M , ZHAO L , WENG LAO I , et al . Well-differentiated papillary mesothelioma: a 17-year single institution experience with a series of 75 cases [J ] . Ann Diagn Pathol , 2019 , 38 : 43 - 50 . DOI: S1092-9134(18)30320-4 http://doi.org/S1092-9134(18)30320-4

DRUT R , QUIJANO G . Multilocular mesothelial inclusion cysts (so-called benign multicystic mesothelioma) of pericardium [J ] . Histopathology , 1999 , 34 ( 5 ): 472 - 474 .

CHURG A , GALATEAU-SALLE F . Well differentiated papillary mesothelial tumor: a new name and new problems [J ] . Mod Pathol , 2022 , 35 ( 10 ): 1327 - 1333 .

WHO Classification of Tumours Editorial Board . WHO classification of tumours: thoracic tumours/urinary and male genital tumours/female genital tumours [M ] . 5th ed. Lyon, France : International Agency for Research on Cancer ; 2021 .

SAUTER J L , DACIC S , GALATEAU-SALLE F , et al . The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification [J ] . J Thorac Oncol , 2022 , 17 ( 5 ): 608 - 622 . DOI: 10.1016/j.jtho.2021.12.014 http://doi.org/10.1016/j.jtho.2021.12.014

World Health Organization . International classification of diseases for oncology (ICD-O), 3rd ed., 1st revision. Geneva, Switzerland: World Health Organization. 2013y [EB/OL ] . https://iris.who.int/handle/10665/96612. https://iris.who.int/handle/10665/96612 https://iris.who.int/handle/10665/96612

World Health Organization . ICD-11 2022 release Geneva, Switzerland : World Health Organization , 2022 . https://www.who.int/news/item/11-02-2022-icd-11-2022-release. https://www.who.int/news/item/11-02-2022-icd-11-2022-release https://www.who.int/news/item/11-02-2022-icd-11-2022-release

GARIAZZO C , GASPARRINI A , MARINACCIO A . Asbestos consumption and malignant mesothelioma mortality trends in the major user countries [J ] . Ann Glob Health , 2023 , 89 ( 1 ): 11 . DOI: 10.5334/aogh.4012 http://doi.org/10.5334/aogh.4012

METINTAS M , HILLERDAL G , METINTAS S . Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort [J ] . Eur Respir J , 1999 , 13 ( 3 ): 523 - 526 .

FARIOLI A , OTTONE M , MORGANTI A G , et al . Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database [J ] . Cancer Med , 2016 , 5 ( 5 ): 950 - 959 .

DONALDSON K , POLAND C A , MURPHY F A , et al . Pulmonary toxicity of carbon nanotubes and asbestos-similarities and differences [J ] . Adv Drug Deliv Rev , 2013 , 65 ( 15 ): 2078 - 2086 .

TESTA J R , CHEUNG M , PEI J M , et al . Germline BAP1 mutations predispose to malignant mesothelioma [J ] . Nat Genet , 2011 , 43 ( 10 ): 1022 - 1025 . DOI: 10.1038/ng.912 http://doi.org/10.1038/ng.912

ATTANOOS R L , CHURG A , GALATEAU-SALLE F , et al . Malignant mesothelioma and its non-asbestos causes [J ] . Arch Pathol Lab Med , 2018 , 142 ( 6 ): 753 - 760 . DOI: 10.5858/arpa.2017-0365-RA http://doi.org/10.5858/arpa.2017-0365-RA

MEZEI G , CHANG E T , MOWAT F S , et al . Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis [J ] . Ann Epidemiol , 2017 , 27 ( 5 ): 348 - 359 .e11. DOI: S1047-2797(17)30287-9 http://doi.org/S1047-2797(17)30287-9

MOOLGAVKAR S H , MEZA R , TURIM J . Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005 [J ] . Cancer Causes Control , 2009 , 20 ( 6 ): 935 - 944 .

ALLEN T C , CAGLE P T , CHURG A M , et al . Localized malignant mesothelioma [J ] . Am J Surg Pathol , 2005 , 29 ( 7 ): 866 - 873 . DOI: 10.1097/01.pas.0000165529.78945.dc http://doi.org/10.1097/01.pas.0000165529.78945.dc

MALPICA A , EUSCHER E D , MARQUES-PIUBELLI M L , et al . Localized malignant peritoneal mesothelioma (LMPeM) in women: a clinicopathologic study of 18 cases [J ] . Am J Surg Pathol , 2022 , 46 ( 10 ): 1352 - 1363 . DOI: 10.1097/PAS.0000000000001924 http://doi.org/10.1097/PAS.0000000000001924

MARCHEVSKY A M , KHOOR A , WALTS A E , et al . Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel [J ] . Mod Pathol , 2020 , 33 ( 2 ): 281 - 296 .

ZHANG Y , PANG M J . Unveiling the mystery: a rare case of localized malignant pericardial mesothelioma-case report [J ] . Front Oncol , 2024 , 14 : 1342748 .

ESPINAL-WITTER R , SERVAIS E L , KLIMSTRA D S , et al . Localized intrapancreatic malignant mesothelioma: a rare entity that may be confused with other pancreatic neoplasms [J ] . Virchows Arch , 2010 , 456 ( 4 ): 455 - 461 .

JIANG Y Q , CAI Y , XU X P , et al . A rare malignant mesothelioma of the tunica vaginalis testis: a case report [J ] . Oncol Lett , 2024 , 27 ( 4 ): 172 . DOI: 10.3892/ol.2024.14305 http://doi.org/10.3892/ol.2024.14305

HUNG Y P , DONG F , DUBUC A M , et al . Molecular characterization of localized pleural mesothelioma [J ] . Mod Pathol , 2020 , 33 ( 2 ): 271 - 280 .

NICHOLSON A G , SAUTER J L , NOWAK A K , et al . EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach [J ] . J Thorac Oncol , 2020 , 15 ( 1 ): 29 - 49 . DOI: S1556-0864(19)33232-0 http://doi.org/S1556-0864(19)33232-0

HUSAIN A N , CHAPEL D B , ATTANOOS R , et al . Guidelines for pathologic diagnosis of mesothelioma: 2023 update of the consensus statement from the international mesothelioma interest group [J ] . Arch Pathol Lab Med , 2024 , 148 ( 11 ): 1251 - 1271 . DOI: 10.5858/arpa.2023-0304-RA http://doi.org/10.5858/arpa.2023-0304-RA

KADOTA K , SUZUKI K , COLOVOS C , et al . A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma [J ] . Mod Pathol , 2012 , 25 ( 2 ): 260 - 271 .

SCHULTE J J , HUSAIN A N . Updates on grading mesothelioma [J ] . Histopathology , 2024 , 84 ( 1 ): 153 - 162 .

ORDÓÑEZ N G . Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases [J ] . Mod Pathol , 2006 , 19 ( 3 ): 373 - 383 .

ORDÓÑEZ N G . Pleomorphic mesothelioma: report of 10 cases [J ] . Mod Pathol , 2012 , 25 ( 7 ): 1011 - 1022 .

LIU S , STAATS P , LEE M , et al . Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients [J ] . Pathology , 2014 , 46 ( 7 ): 604 - 609 .

OYAMA T , GOTO T , AMEMIYA K . Mixed micropapillary patterns found in malignant pleural mesothelioma with possibly worsened prognostic implication [J ] . Thorac Cancer , 2022 , 13 ( 7 ): 1098 - 1099 . DOI: 10.1111/1759-7714.14364 http://doi.org/10.1111/1759-7714.14364

ROSEN L E , KARRISON T , ANANTHANARAYANAN V , et al . Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study [J ] . Mod Pathol , 2018 , 31 ( 4 ): 598 - 606 .

ALCHAMI F S , ATTANOOS R L , BAMBER A R . Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma [J ] . J Clin Pathol , 2017 , 70 ( 2 ): 179 - 182 . DOI: 10.1136/jclinpath-2016-203993 http://doi.org/10.1136/jclinpath-2016-203993

KLEBE S , BROWNLEE N A , MAHAR A , et al . Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases [J ] . Mod Pathol , 2010 , 23 ( 3 ): 470 - 479 .

刘绮颖 , 陈庆明 , 喻林 , 等 . 肉瘤样恶性间皮瘤的临床病理分析 [J ] . 中华病理学杂志 , 2014 , 43 ( 6 ): 364 - 369 .

LIU Q Y , CHEN Q M , YU L , et al . Sarcomatoid malignant mesothelioma: A clinicopathologic and immunohistochemical analysis of 22 cases [J ] . Chin J Pathol , 2014 , 43 ( 6 ): 364 - 369 .

GALATEAU-SALLÉ F , ATTANOOS R , GIBBS A R , et al . Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases [J ] . Am J Surg Pathol , 2007 , 31 ( 5 ): 711 - 716 .

CANTIN R , AL-JABI M , MCCAUGHEY W T . Desmoplastic diffuse mesothelioma [J ] . Am J Surg Pathol , 1982 , 6 ( 3 ): 215 - 222 .

KLEBE S , MAHAR A , HENDERSON D W , et al . Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review [J ] . Mod Pathol , 2008 , 21 ( 9 ): 1084 - 1094 .

DACIC S , STANG N L , HUSAIN A , et al . Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas [J ] . Mod Pathol , 2020 , 33 ( 2 ): 255 - 262 .

SALLE F G , LE STANG N , TIRODE F , et al . Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the international mesothelioma panel from the MESOPATH reference center [J ] . J Thorac Oncol , 2020 , 15 ( 6 ): 1037 - 1053 . DOI: S1556-0864(20)30174-X http://doi.org/S1556-0864(20)30174-X

FORTAREZZA F , PEZZUTO F , MANIGLIO S , et al . Adverse prognostic impact of transitional and pleomorphic patterns in pleural nonepithelioid mesothelioma: insights from comprehensive analysis and reticulin stain [J ] . Arch Pathol Lab Med , 2024 .

GALATEAU SALLE F , STANG N L , NICHOLSON A G , et al . New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center [J ] . J Thorac Oncol , 2018 , 13 ( 8 ): 1189 - 1203 . DOI: S1556-0864(18)30551-3 http://doi.org/S1556-0864(18)30551-3

FOREST F , PATOIR A , DAL COL P , et al . Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications [J ] . Pathology , 2018 , 50 ( 6 ): 635 - 641 .

ZHANG Y Z , BRAMBILLA C , MOLYNEAUX P L , et al . Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade [J ] . Histopathology , 2020 , 77 ( 3 ): 423 - 436 . DOI: 10.1111/his.14127 http://doi.org/10.1111/his.14127

ZHANG Y Z , BRAMBILLA C , MOLYNEAUX P L , et al . Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in biopsy-heavy setting: an external validation study of 563 cases [J ] . Am J Surg Pathol , 2020 , 44 ( 3 ): 347 - 356 . DOI: 10.1097/PAS.0000000000001416 http://doi.org/10.1097/PAS.0000000000001416

WANG Q , XU C W , WANG W X , et al . Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma [J ] . Thorac Cancer , 2023 , 14 ( 26 ): 2715 - 2731 . DOI: 10.1111/1759-7714.15022 http://doi.org/10.1111/1759-7714.15022

POPAT S , BAAS P , FAIVRE-FINN C , et al . Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2022 , 33 ( 2 ): 129 - 142 .

TÜRK İ , FINDIK G , ÇETIN M , et al . Importance of histopathological grading for treatment selection in malignant mesothelioma [J ] . Thorac Cardiovasc Surg , 2023 , 71 ( 6 ): 497 - 503 . DOI: 10.1055/s-0043-1761209 http://doi.org/10.1055/s-0043-1761209

SCHULTE J J , CHAPEL D B , ATTANOOS R , et al . Comparison of nuclear grade, necrosis, and histologic subtype between biopsy and resection in pleural malignant mesothelioma: an international multi-institutional analysis [J ] . Am J Clin Pathol , 2021 , 156 ( 6 ): 989 - 999 . DOI: 10.1093/ajcp/aqab054 http://doi.org/10.1093/ajcp/aqab054

VALENTE K , BLACKHAM A U , LEVINE E , et al . A histomorphologic grading system that predicts overall survival in diffuse malignant peritoneal mesothelioma with epithelioid subtype [J ] . Am J Surg Pathol , 2016 , 40 ( 9 ): 1243 - 1248 . DOI: 10.1097/PAS.0000000000000696 http://doi.org/10.1097/PAS.0000000000000696

PEZZUTO F , VIMERCATI L , FORTAREZZA F , et al . Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report [J ] . Diagn Pathol , 2021 , 16 ( 1 ): 64 . DOI: 10.1186/s13000-021-01125-z http://doi.org/10.1186/s13000-021-01125-z

CHAPEL D B , SCHULTE J J , ABSENGER G , et al . Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases [J ] . Mod Pathol , 2021 , 34 ( 2 ): 380 - 395 .

FUCHS T L , CHOU A , AKSOY Y , et al . A critical assessment of current grading schemes for diffuse pleural mesothelioma with a proposal for a novel mesothelioma weighted grading scheme (MWGS) [J ] . Am J Surg Pathol , 2022 , 46 ( 6 ): 774 - 785 .

AKSOY Y , CHOU A , MAHJOUB M , et al . A novel prognostic nomogram for predicting survival in diffuse pleural mesothelioma [J ] . Pathology , 2023 , 55 ( 4 ): 449 - 455 .

GALEANO B , SMITH C J , YI E S , et al . Ki-67 proliferation index is associated with tumor grade and survival in pleural epithelioid mesotheliomas [J ] . Am J Surg Pathol , 2024 , 48 ( 5 ): 615 - 622 .

HUNG Y P , CHIRIEAC L R . Molecular and immunohistochemical testing in mesothelioma and other mesothelial lesions [J ] . Arch Pathol Lab Med , 2024 , 148 ( 5 ): e77 - e89 . DOI: 10.5858/arpa.2023-0213-RA http://doi.org/10.5858/arpa.2023-0213-RA

NASO J R , TSUJI S , CHURG A . HEG1 is a highly specific and sensitive marker of epithelioid malignant mesothelioma [J ] . Am J Surg Pathol , 2020 , 44 ( 8 ): 1143 - 1148 . DOI: 10.1097/PAS.0000000000001469 http://doi.org/10.1097/PAS.0000000000001469

NAKAGIRI T , AMATYA V J , KUSHITANI K , et al . SPARC is a novel positive immunohistochemical marker of epithelioid mesothelioma to differentiate it from lung adenocarcinoma and/or squamous cell carcinoma [J ] . Am J Surg Pathol , 2024 , 48 ( 2 ): 140 - 149 .

KIMURA N , HASEGAWA M , HIROSHIMA K . SMARCB1/INI1/BAF47- deficient pleural malignant mesothelioma with rhabdoid features [J ] . Pathol Int , 2018 , 68 ( 2 ): 128 - 132 . DOI: 10.1111/pin.12623 http://doi.org/10.1111/pin.12623

HUNG Y P , DONG F , WATKINS J C , et al . Identification of ALK rearrangements in malignant peritoneal mesothelioma [J ] . JAMA Oncol , 2018 , 4 ( 2 ): 235 - 238 . DOI: 10.1001/jamaoncol.2017.2918 http://doi.org/10.1001/jamaoncol.2017.2918

XING D Y , BANET N , SHARMA R , et al . Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study [J ] . Hum Pathol , 2018 , 72 : 160 - 166 . DOI: S0046-8177(17)30463-X http://doi.org/S0046-8177(17)30463-X

BERG K B , CHURG A . GATA3 immunohistochemistry for distinguishing sarcomatoid and desmoplastic mesothelioma from sarcomatoid carcinoma of the lung [J ] . Am J Surg Pathol , 2017 , 41 ( 9 ): 1221 - 1225 . DOI: 10.1097/PAS.0000000000000825 http://doi.org/10.1097/PAS.0000000000000825

TERRA S B S P , RODEN A C , AUBRY M C , et al . Utility of immunohistochemistry for MUC4 and GATA3 to aid in the distinction of pleural sarcomatoid mesothelioma from pulmonary sarcomatoid carcinoma [J ] . Arch Pathol Lab Med , 2021 , 145 ( 2 ): 208 - 213 .

TERRA S , RODEN A C , YI E S , et al . Loss of methylthioadenosine phosphorylase by immunohistochemistry is common in pulmonary sarcomatoid carcinoma and sarcomatoid mesothelioma [J ] . Am J Clin Pathol , 2022 , 157 ( 1 ): 33 - 39 .

RIENZO A D , CHIRIEAC L R , HUNG Y P , et al . Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma [J ] . J Pathol , 2021 , 253 ( 1 ): 68 - 79 .

CHAPEL D B , HORNICK J L , BARLOW J , et al . Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma [J ] . Mod Pathol , 2022 , 35 ( 10 ): 1383 - 1397 .

PETERS S , SCHERPEREEL A , CORNELISSEN R , et al . First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 [J ] . Ann Oncol , 2022 , 33 ( 5 ): 488 - 499 . DOI: 10.1016/j.annonc.2022.01.074 http://doi.org/10.1016/j.annonc.2022.01.074

CHAPEL D B , STEWART R , FURTADO L V , et al . Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays [J ] . Hum Pathol , 2019 , 87 : 11 - 17 . DOI: S0046-8177(19)30017-6 http://doi.org/S0046-8177(19)30017-6

BRCIC L , KLIKOVITS T , MEGYESFALVI Z , et al . Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study [J ] . Transl Lung Cancer Res , 2021 , 10 ( 4 ): 1594 - 1607 .

GAZIVODA V P , KANGAS-DICK A W , GREENBAUM A A , et al . Expression of PD-L1 in patients with malignant peritoneal mesothelioma: a pilot study [J ] . J Surg Res , 2022 , 277 : 131 - 137 . DOI: 10.1016/j.jss.2022.04.005 http://doi.org/10.1016/j.jss.2022.04.005

BUENO R , STAWISKI E W , GOLDSTEIN L D , et al . Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations [J ] . Nat Genet , 2016 , 48 ( 4 ): 407 - 416 . DOI: 10.1038/ng.3520 http://doi.org/10.1038/ng.3520

HMELJAK J , SANCHEZ-VEGA F , HOADLEY K A , et al . Integrative molecular characterization of malignant pleural mesothelioma [J ] . Cancer Discov , 2018 , 8 ( 12 ): 1548 - 1565 . DOI: 10.1158/2159-8290.CD-18-0804 http://doi.org/10.1158/2159-8290.CD-18-0804

DAGOGO-JACK I , MADISON R W , LENNERZ J K , et al . Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape [J ] . JCO Precis Oncol , 2022 , 6 : e2100422 .

LADANYI M . Implications of P16/CDKN2A deletion in pleural mesotheliomas [J ] . Lung Cancer , 2005 , 49 ( Suppl 1 ): S95-S98 .

ILLEI P B , RUSCH V W , ZAKOWSKI M F , et al . Homozygous deletion of CDKN 2 A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas [J ] . Clin Cancer Res , 2003 , 9 ( 6 ): 2108 - 2113 .

BRCIC L , STANG N L , GALLOB F , et al . A combination of MTAP and p16 immunohistochemistry can substitute for CDKN 2 A fluorescence in situ hybridization in diagnosis and prognosis of pleural mesothelio mas [J ] . Arch Pathol Lab Med , 2023 , 147 ( 3 ): 313 - 322 .

SA-NGIAMWIBOOL P , HAMASAKI M , KINOSHITA Y , et al . Usefulness of NF 2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: a multi-institutional study [J ] . Lung Cancer , 2023 , 175 : 27 - 35 .

MARTIN S D , CHEUNG S , CHURG A . Immunohistochemical demonstration of merlin/ NF 2 loss in mesothelioma [J ] . Mod Pathol , 2023 , 36 ( 1 ): 100036 .

孙蒙 , 柏乾明 , 赵露 , 等 . 荧光原位杂交检测 p 16基因缺失在恶性间皮瘤中的诊断价值 [J ] . 中华病理学杂志 , 2020 , 49 ( 12 ): 1314 - 1316 .

SUN M , BAI Q M , ZHAO L , et al . Detection of p 16 by fluorescence in situ hybridization and immunohistochemistry in malignant mesothelioma [J ] . Chin J Pathol , 2020 , 49 ( 12 ): 1314 - 1316 .

SMITH-HANNAH A , NAOUS R . Primary peritoneal epithelioid mesothelioma of clear cell type with a novel VHL gene mutation: a case report [J ] . Hum Pathol , 2019 , 83 : 199 - 203 .

MICHAL M , KRAVTSOV O , ROSS J S , et al . Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features [J ] . Genes Chromosomes Cancer , 2023 , 62 ( 5 ): 267 - 274 .

ARGANI P , LIAN D W Q , AGAIMY A , et al . Pediatric mesothelioma with ALK fusions: a molecular and pathologic study of 5 cases [J ] . Am J Surg Pathol , 2021 , 45 ( 5 ): 653 - 661 .

PANAGOPOULOS I , THORSEN J , GORUNOVA L , et al . RNA sequencing identifies fusion of the EWSR 1 and YY 1 genes in mesothelioma with t(14;22)(q32;q12) [J ] . Genes Chromosomes Cancer , 2013 , 52 ( 8 ): 733 - 740 .

DERMAWAN J K , TORRENCE D , LEE C H , et al . EWSR1: : YY1 fusion positive peritoneal epithelioid mesothelioma harbors mesothelioma epigenetic signature: report of 3 cases in support of an emerging entity [J ] . Genes Chromosomes Cancer , 2022 , 61 ( 10 ): 592 - 602 .

DESMEULES P , JOUBERT P , ZHANG L , et al . A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR 1/ FUS - ATF 1 fusions [J ] . Am J Surg Pathol , 2017 , 41 ( 7 ): 980 - 988 .

WHITAKER D , HENDERSON D W , SHILKIN K B . The concept of mesothelioma in situ : implications for diagnosis and histogenesis [J ] . Semin Diagn Pathol , 1992 , 9 ( 2 ): 151 - 161 .

CHURG A , HWANG H , TAN L , et al . Malignant mesothelioma in situ [J ] . Histopathology , 2018 , 72 ( 6 ): 1033 - 1038 .

CHURG A , GALATEAU-SALLE F , RODEN A C , et al . Malignant mesothelioma in situ : morphologic features and clinical outcome [J ] . Mod Pathol , 2020 , 33 ( 2 ): 297 - 302 .

DANUZZO F , RAVEGLIA F , SPINELLI F , et al . Pleural mesothelioma in situ : a comprehensive review [J ] . Eur J Cancer Prev , 2024 , 33 ( 6 ): 545 - 551 .

SYMES E , TJOTA M , CODY B , et al . Mesothelioma in situ of the peritoneum: report of three cases and review of the literature [J ] . Histopathology , 2024 , 84 ( 3 ): 492 - 506 .

KOBAYASHI Y , YASUHARA Y , ARAI H , et al . Mesothelioma in situ of the spermatic cord arising from a patent processus vaginalis: a case report [J ] . Urol J , 2020 , 17 ( 6 ): 671 - 673 .

GALATEAU-SALLE F , HAMILTON T , MACNEILL A , et al . Mesothelioma in situ mimicking well-differentiated papillary mesothelial tumor [J ] . Am J Surg Pathol , 2023 , 47 ( 5 ): 611 - 617 .

HIDAKA K , TAKEDA T , KINOSHITA Y , et al . Development of mesothelioma in situ and its progression to invasive disease observed in a patient with uncontrolled pleural effusions for 15 years [J ] . Pathol Int , 2020 , 70 ( 12 ): 1009 - 1014 .

KLEBE S . Progression of mesothelioma in situ to invasive disease 4 years and 10 months after initial diagnosis [J ] . Pathology , 2022 , 54 ( 3 ): 384 - 386 .

NASO J R , CHURG A . Claudin-4 shows superior specificity for mesothelioma vs non-small cell lung carcinoma compared with MOC-31 and Ber-EP4 [J ] . Hum Pathol , 2020 , 100 : 10 - 14 .

STEVERS M , RABBAN J T , GARG K , et al . Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF 7 and CDC 42 [J ] . Mod Pathol , 2019 , 32 ( 1 ): 88 - 99 .

HUNG Y P , DONG F , TORRE M , et al . Molecular characterization of diffuse malignant peritoneal mesothelioma [J ] . Mod Pathol , 2020 , 33 ( 11 ): 2269 - 2279 .

SHAH I A , SALVATORE J R , KUMMET T , et al . Pseudomesotheliomatous carcinoma involving pleura and peritoneum: a clinicopathologic and immunohistochemical study of three cases [J ] . Ann Diagn Pathol , 1999 , 3 ( 3 ): 148 - 159 .

PRABHAKARAN S , HOCKING A , KIM C , et al . The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas [J ] . Hum Pathol , 2020 , 105 : 1 - 8 . DOI: S0046-8177(20)30167-2 http://doi.org/S0046-8177(20)30167-2

CHURG A , LE STANG N , DACIC S , et al . Solid papillary mesothelial tumor [J ] . Mod Pathol , 2022 , 35 ( 1 ): 69 - 76 .

AGAIMY A , BRCIC L , BRISKI L M , et al . NR 4 A 3 fusions characterize a distinctive peritoneal mesothelial neoplasm of uncertain biological potential with pure adenomatoid/microcystic morphology [J ] . Genes Chromosomes Cancer , 2023 , 62 ( 5 ): 256 - 266 .

DERAKHSHAN F , IONESCU D , CHEUNG S , et al . Use of programmed death ligand-1 (PD-L1) staining to separate sarcomatoid malignant mesotheliomas from benign mesothelial reactions [J ] . Arch Pathol Lab Med , 2020 , 144 ( 2 ): 185 - 188 . DOI: 10.5858/arpa.2019-0370-OA http://doi.org/10.5858/arpa.2019-0370-OA

MEYERHOFF R R , YANG C F , SPEICHER P J , et al . Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database [J ] . J Surg Res , 2015 , 196 ( 1 ): 23 - 32 . DOI: 10.1016/j.jss.2015.01.043 http://doi.org/10.1016/j.jss.2015.01.043

SINGHI A D , KRASINSKAS A M , CHOUDRY H A , et al . The prognostic signifi cance of BAP 1, NF 2, and CDKN 2 A in malignant peritoneal mesothelioma [J ] . Mod Pathol , 2016 , 29 ( 1 ): 14 - 24 .

MCGREGOR S M , MCELHERNE J , MINOR A , et al . BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN 2 A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma [J ] . Hum Pathol , 2017 , 60 : 86 - 94 .

BAUMANN F , FLORES E , NAPOLITANO A , et al . Mesothelioma patients with germline BAP 1 mutations have 7-fold improved long-term survival [J ] . Carcinogenesis , 2015 , 36 ( 1 ): 76 - 81 .

BLUM Y , MEILLER C , QUETEL L , et al . Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications [J ] . Nat Commun , 2019 , 10 ( 1 ): 1333 . DOI: 10.1038/s41467-019-09307-6 http://doi.org/10.1038/s41467-019-09307-6

ALCALA N , MANGIANTE L , LE-STANG N , et al . Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions [J ] . EBioMedicine , 2019 , 48 : 191 - 202 . DOI: S2352-3964(19)30601-2 http://doi.org/S2352-3964(19)30601-2

BROSSEAU S , DANEL C , SCHERPEREEL A , et al . Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the bio-MAPS cohort [J ] . Clin Lung Cancer , 2019 , 20 ( 5 ): e564 - e575 .

SOBHANI N , ROVIELLO G , PIVETTA T , et al . Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma [J ] . Mol Biol Rep , 2019 , 46 ( 3 ): 2713 - 2720 . DOI: 10.1007/s11033-019-04715-9 http://doi.org/10.1007/s11033-019-04715-9

KLEBE S , JUDGE M , BRCIC L , et al . Mesothelioma in the pleura, pericardium and peritoneum: recommendations from the international collaboration on cancer reporting (ICCR) [J ] . Histopathology , 2024 , 84 ( 4 ): 633 - 645 . DOI: 10.1111/his.15106 http://doi.org/10.1111/his.15106

WITTEKIND C , GOSPODAROWICZ M , SOBIN L . TNM classification of malignant tumours, 7th edition [M ] . UICC, 8th ed . Chicago : Wiley Blackwell , 2009 .

BRIERLEY J D , GOSPODAROWICZ M K , WITTEKIND C , eds. TNM classification of malignant tumours [M ] . 8th ed. Chicago : Wiley Blackwell , 2016 .

RUSCH V W , CHANSKY K , NOWAK A K , et al . Malignant pleural mesothelioma. In: AJCC cancer staging manual [M ] . 8th ed. Springer , 2017 : 457 - 468 .

GILLY F N , COTTE E , BRIGAND C , et al . Quantitative prognostic indices in peritoneal carcinomatosis [J ] . Eur J Surg Oncol , 2006 , 32 ( 6 ): 597 - 601 .

SALO S A S , LANTTO E , ROBINSON E , et al . Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma: national cohort study [J ] . Sci Rep , 2020 , 10 ( 1 ): 13257 . DOI: 10.1038/s41598-020-70044-8 http://doi.org/10.1038/s41598-020-70044-8

CARBONE M . Transitional mesothelioma and artificial intelligence: do we need one more subtype? And do we need computers to identify them? [J ] . J Thorac Oncol , 2020 , 15 ( 6 ): 884 - 887 . DOI: S1556-0864(20)30289-6 http://doi.org/S1556-0864(20)30289-6

HARTMAN D J . Applications of artificial intelligence in lung pathology [J ] . Surg Pathol Clin , 2024 , 17 ( 2 ): 321 - 328 . DOI: 10.1016/j.path.2023.11.013 http://doi.org/10.1016/j.path.2023.11.013

Views

635

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasms (2025 edition)

Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition)

China Anti-Cancer Association guideline for diagnosis and treatment of cancer of multiple and unknown primaries (2023 edition)

China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)

Related Author

The Society of Breast Cancer China Anti-Cancer Association

Breast Oncology Group of the Oncology Branch of the Chinese Medical Association

of Neuroendocrine Neoplasm of China Anti-Cancer Association Society

Breast Cancer China Anti-Cancer Association The Society of

of the Oncology Branch of the Chinese Medical Association Breast Oncology Group

Society of Cancer of Multiple and Unknown Primary of China Anti-Cancer Association Yuguang

of Neuroendocrine Neoplasm of China Anti-Cancer Association Society

Hao WANG

Related Institution

Department of Radiotherapy, Qingdao Hospital, University of Health and Rehabilitation Science (Qingdao Municipal Hospital)

Oncology Medical Center, Peking University International Hospital

Department of Thyroid and Breast Surgery, The Fourth Affiliated Hospital of Anhui Medical University (Affiliated Chaohu Hospital)

General Practice, Hefei First People’s Hospital

Pathology Department, The Fourth Affiliated Hospital of Anhui Medical University (Affiliated Chaohu Hospital)

AI问答

⁰